THE SCIENCE BEHIND HEXAGHEN
DESCRIPTION: Hexaghen Fastsorb tablets belong to a new class of orally effective IGF-1 (Insulin-Like Growth Factor-1) stimulating compounds. Hexaghen is designed to stimulate the endogenous production of IGF-1, causing a quick and dramatic rise in serum free IGF-1 levels. The Hexaghen IGF-1 Optimizing complex modulates critical endocrine functions, and promotes prolonged elevation of serum IGF-1 levels for progressive anabolic muscle growth benefits. Hexaghen utilizes a patent pending FASTSORB sub-buccal delivery system for rapid absorption and maximum bioavailability.
ACTIVE COMPOUNDS:
Hexaghen, sub-buccal tablets for oral administration contain IGF-1 Optimizing synergistic compounds:
GHRP-2 Hexapeptide Acetate
cis -4, 17(20)-pregnadiene-3,16-dione
trans-4, 17(20)-pregnadiene-3,16-dione
CLINICALaPHARMACOLOGY:aIGF-1 poses some unique anabolic characteristics and is one of the most potent natural activators of the AKT signaling pathway, a stimulator of cell growth and multiplication. Attention was first turned to IGF-1 when scientists researching growth hormone discovered that GH’s influence on IGF-1 was the responsible factor for the anabolic effects associated with growth hormone administration and elevation. In fact, while GH has direct fat burning effects as it metabolizes stored body fat, its muscle building effects are actually attributed to its effects on increasing IGF-1 levels. Therefore, it is IGF-1 and not GH that directly mediates muscle cell hyperplasia and muscle growth at the cellular level. IGF-1 is thought to be the critical mediator as it stimulates both the differentiation and proliferation of myoblasts (muscle cells), resulting in muscle growth. IGF-1 also enhances muscle growth by increasing amino acid uptake and protein synthesis.
Hexaghen’s active compounds work synergistically to rapidly stimulate GH production, which promotes synthesis of IGF-1, increasing both total and free IGF-1 levels. IGF-1 is an important peptide hormone that is involved in regulating growth and development of muscle tissue. Its primary action is mediated by binding to specific IGF-1 receptors present on many cell types in many tissues. The free form IGF-1 fraction is highly bio-active in comparison to the IGF-1 bound to IGF Binding Proteins (IGFBPs). IGF-1 is the principal hormonal mediator of growth in the body. In the cascade of events leading to a surge in IGF-1 production and levels, Hexaghen stimulated growth hormone is metabolized by the liver and poteniates the synthesis and secretion of IGF-1.
Muscle tissue has an abundance of IGF-1 receptors. When serum IGF-1 binds to these receptor sites on muscle tissue, it stimulates the following anabolic actions and growth processes in humans, including increasing the number and size of muscle cells:
* Regulator of cell growth and development.
* Regulator of cellular DNA synthesis.
* Mediates muscle cell hyperplasia and muscle fiber development initiation and maturation.
* Stimulates the growth and size of muscle cells.
* Stimulates glucose uptake by myoblasts (muscle precursor cells), which fuels their growth and development into muscle fiber cells.
* Increases muscle cell uptake of amino acids, uses as building blocks of muscle protein molecules.
* Increases nitrogen retention and a greater food conversion efficiency.
* Reduces nitrogen excretion.
* Improves wound healing.
* Stimulates muscle protein synthesis.
* Preferentially stimulates the growth of lean tissue.
* Stimulates mitogenic (cell replication) activities that lead to an increased number of muscle cells in the body.
* Vital for muscle repair and regeneration.
* Causes improvements in body composition, demonstrating a decrease in body fat mass and a profound increase in lean body mass.
The relationship within the endocrine / IGF-1 axis is a complex system. Scientists have recently identified other factors that play a critical role in effecting IGF-1 levels. Approximately 98% of IGF-1 is bound to one of several insulin-like growth factor binding proteins (IGFBP). IGFBP-3, the most abundant protein, accounts for 80% of all IGF-1 binding. Research has demonstrated that reducing IGF-1 binding proteins and maintaining higher levels of free IGF-1 is correlated to improved anabolic effects and muscle development. Hexaghen’s IGF-1 optimizing action also involves the sustained stimulation of thyroid hormone production, which mediates IGFBP levels, favorable to achieving sustainable high free IGF-1 levels to further enhance muscle growth.
Thyroid function is associated with enhancing IGF-1 bio-active tissue levels and further increasing the rate of protein synthesis. As IGF-1 levels are increased, a series of negative feedback controls involving the thyroid endocrine axis are triggered to keep IGF-1 levels within a narrow physiological range. From examining the relationships between GH, IGF-1 production, IGF-1 levels, free IGF-1, IGFBP, and thyroid function, MuscleMeds researchers determined a correlation between IGF-1 production and bio-effectiveness related to thyroid stimulation. Hexaghen’s synergistic thyroid involvement results in sustaining higher total and free IGF-1 levels for longer periods of time, thereby extending the overall desired IGF-1 anabolic effects.
Research and Development
The muscle building effects of IGF-1 have been well known and medically documented for years. But, the controlling factors regulating the body’s natural output have challenged researchers. Synthetic IGF-1 has been produced by major biotech pharmaceutical companies on a large scale using recombinant DNA technology. These synthetic forms must be administered via injection dosing. The development of an orally effective IGF-1 enhancing compound has long been a major global objective of biotechnologists.
After years of extensive research and laboratory analysis, MuscleMeds researchers discovered a unique IGF-1 stimulating hexapeptide (GHRP-2 Hexapeptide Acetate). This unique six chain peptide was found to have potent IGF-1 stimulating effects, based on using injection dosing. The development of an effective oral dosage form for GHRP-2 Hexapeptide posed some biotechnical challenges. The first challenge was the stability and effectiveness when administered orally, because conventional oral dosing (such as tablets, capsules, liquids and softgels) was ineffective due to the gastrointestinal destruction of the GHRP-2 hexapeptide. As with other peptide substances, GHRP-2 hexapetide is subject to destruction (breakdown) in the gastrointestinal system, which eliminates the effectiveness and ability to reach the hypothalamus-pituitary axis. In order to create a product that is suitable for oral administration of the Hexaghen GHRP-2 Hexapeptide acetate, MuscleMeds scientists employed the utilization of their proprietary FastSorb sub-buccal delivery system technology. MuscleMeds’ testing using Hexaghen Fastsorb tablets proved to be the viable solution for providing a maximally effective oral delivery dosage system. The fastsorb tablet dosage form allows for the long hexapeptide to bypass degradation and be absorbed in the buccul cavity directly into the blood stream to stimulate the hypothalamus-pituitary GH / IGF-1 axis.
The next challenge was to manipulate endocrine functions at the GH/IGF-1 Axis to override the negative feedback inhibition of IGFBP-3 (Insulin-Like Binding Growth Factor Protein-3) to supercede the narrow physiological range and achieve the maximum IGF-1 output threshold. Approximately 98% of IGF-1 is typically bound to one of 6 binding proteins (IGFBP). IGFBP-3, the most abundant protein, accounts for 80% of all IGF binding. This means that most of the IGF-1 that you produce is bound to IGFBP-3 and not able to bind to specific IGF-1 receptors present on muscle cells and carry out its anabolic actions. To overcome this MuscleMeds researchers found that there was a direct correlation between TSH (Thyroid Stimulating Hormone) and IGFBP-3.
As a result of this researched based product development effort, Hexaghen features a unique IGF-1 Optimizing Complex. Hexaghen’s novel ingredient composition and proprietary pharmaceutical based liposomal sub-buccal delivery system, stabilizes the bioactives for rapid and high levels of absorption directly into the blood stream primarily through buccal cavity (mouth) absorption. Oral mucosal dosage delivery (transmucosally) is an alternative method of systemic nutrient delivery, which offers several advantages as the oral mucosa is highly vascularised with absorptive abilities. Therefore, Hexaghen’s active compounds are absorbed through the oral mucosa directly enter the bloodstream, bypassing the gastrointestinal tract and first-pass metabolism in the liver. This improves the bioeffectiveness of delivery into the body, making it possible to maximally stimulate the levels of IGF-1 through a series of endocrine medicated events: Hexaghen stimulates GHRP, GH, and IGF-1 levels, modulates thyroid function, and decreases IGFBP for the attainment of maximum threshold IGF-1 output. Hexaghen’s ability to significantly increase free IGF-1 levels exerts extremely powerful anabolic effects by directly mediating muscle cell differentiating, proliferation, and hyperplasia.
